Holen Sie sich die Stockscreener-App
2.16
1.41%
0.03
Schlusskurs vom Vortag:
$2.13
Offen:
$2.17
24-Stunden-Volumen:
6,740
Relative Volume:
0.36
Marktkapitalisierung:
$5.31M
Einnahmen:
$453.80K
Nettoeinkommen (Verlust:
$-1.03M
KGV:
-3.0067
EPS:
-0.7184
Netto-Cashflow:
-
1W Leistung:
-1.82%
1M Leistung:
-18.80%
6M Leistung:
-11.11%
1J Leistung:
-88.46%
1-Tages-Spanne:
$2.16
$2.2126
1-Wochen-Bereich:
$2.11
$2.44
52-Wochen-Spanne:
$2.0101
$41.12
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Company Profile
Firmenname
X T L Biopharmaceuticals Ltd Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare XTLB vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XTLB
X T L Biopharmaceuticals Ltd Adr
|
2.16 | 5.41M | 453.80K | -1.03M | 0 | -0.7184 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
X T L Biopharmaceuticals Ltd Adr Stock (XTLB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2015-05-08 | Eingeleitet | H.C. Wainwright | Buy |
X T L Biopharmaceuticals Ltd Adr Aktie (XTLB) Neueste Nachrichten
XTL Biopharmaceuticals (XTLB) Trades Flat at $2.56, Sitting Midway Between Support and ResistanceLiquidity Sweep - dars.gov.et
XTL Biopharmaceuticals Faces Derivative Action Bid Over Failed Social Proxy Acquisition - TipRanks
XTL Biopharmaceuticals Ltd. Sponsored ADR Revenue Breakdown – FWB:HHB0 - TradingView
XTL Biopharmaceuticals Regains Nasdaq Compliance and Enters One-Year Monitoring Period - The Globe and Mail
XTLB Stock Price, Quote & Chart - ChartMill
Enterprise value to EBITDA forward of XTL Biopharmaceuticals Ltd. Sponsored ADR – LSX:A41X7J - TradingView
XTL Biopharmaceuticals Completes Psyga Bio Acquisition, Refocuses on Psychedelic Medicine - TipRanks
XTL Biopharmaceuticals Shareholders Approve Psyga Bio Acquisition and Major Capital Increase - TipRanks
Wondering what's happening in today's after-hours session? - ChartMill
XTL Biopharmaceuticals Adjourns Extraordinary Shareholder Meeting to June 29, 2026 - TipRanks
XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis $XTLB - MarketBeat
XTLB - Finviz
XTL Biopharmaceuticals Faces Added Nasdaq Delisting Risk Over Late 2025 Annual Report - TipRanks
XTL Biopharmaceuticals faces additional Nasdaq delisting risk - Investing.com
Eastern International Ltd. expands board, appoints two new directors - Investing.com
XTL Biopharmaceuticals Calls June 22, 2026 Meeting to Approve Psyga Bio Acquisition and Capital Raise - The Globe and Mail
SMX increases authorized shares for incentive plan and grants restricted stock units - Investing.com
XTL Biopharmaceuticals Wins Conditional Nasdaq Listing Reprieve Tied to Psyga Bio Deal - TipRanks
XTL Biopharmaceuticals Delays 20-F Amid Subsidiary Liquidation - TipRanks
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.57% - Investing.com
XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline - TipRanks
XTL Biopharmaceuticals to acquire Psyga Bio for 40% stake - Investing.com
Triangle DescendingStock ScreenerCharts - Finviz
Top GainersStock ScreenerSnapshot - Finviz
XTL Biopharmaceuticals Ltd ADR Each REPR 40 share price | XTLB - Hargreaves Lansdown
Debt to assets ratio of XTL Biopharmaceuticals Ltd. Sponsored ADR – GETTEX:HHB0 - TradingView
Total assets of XTL Biopharmaceuticals Ltd. Sponsored ADR – SWB:HHB0 - TradingView
Free cash flow per share of XTL Biopharmaceuticals Ltd. Sponsored ADR – GETTEX:HHB0 - TradingView
XTL Biopharmaceuticals Ltd. Sponsored ADR Trade Ideas — SWB:HHB0 - TradingView
XTL Biopharmaceuticals Ltd. Sponsored ADR Cash Flow – LSX:A41X7J - TradingView
Average basic shares outstanding of XTL Biopharmaceuticals Ltd. Sponsored ADR – LSX:A41X7J - TradingView
Total operating expenses of XTL Biopharmaceuticals Ltd. Sponsored ADR – LSX:A41X7J - TradingView — Track All Markets
XTL Biopharmaceuticals Ltd. Sponsored ADR Statistics – LSX:A41X7J - TradingView
Return on assets % of XTL Biopharmaceuticals Ltd. Sponsored ADR – LS:A41X7J - TradingView
Basic earnings per share (basic EPS) of XTL Biopharmaceuticals Ltd. Sponsored ADR – LSX:A41X7J - TradingView — Track All Markets
XTL Biopharmaceuticals Ltd. Sponsored ADR Earnings and Revenue – MUN:HHB0 - TradingView
Diluted shares outstanding of XTL Biopharmaceuticals Ltd. Sponsored ADR – FWB:HHB0 - TradingView
XTL Biopharmaceuticals Ltd. Sponsored ADR Income Statement – FWB:HHB0 - TradingView
Net margin % of XTL Biopharmaceuticals Ltd. Sponsored ADR – FWB:HHB0 - TradingView
XTL Biopharmaceuticals Ltd. Sponsored ADR Financial Statements – FWB:HHB0 - TradingView
XTL Biopharmaceuticals to Implement One-for-Four ADS Reverse Split Effective March 25, 2026 - The Globe and Mail
XTL Biopharmaceuticals Announces ADS Ratio Change - Yahoo Finance
ADR Ratio Change - Yahoo Finance
XTL Biopharmaceuticals Ends Acquisition Talks After NeuroNOS LOI Expires - TipRanks
XTL Biopharmaceuticals faces Nasdaq delisting notice - Investing.com
XTL Biopharmaceuticals shareholders approve share capital increase and private placement - Investing.com
XTL Biopharmaceuticals Ltd ADR (NASDAQ: XTLB) Stock Price, News & Analysis - kalkine.ca
The trading volume of these stocks is deviating from the norm in today's session. - ChartMill
XTL Biopharmaceuticals Moves to Acquire NeuroNOS Stake from Beyond Air and Plans $2 Million Private Placement - TipRanks
XTL Biopharmaceuticals Takes Major Impairment on The Social Proxy in First-Half 2025 Results - TipRanks
XTL Biopharmaceuticals Faces Nasdaq Bid-Price Deficiency, Given Until June 2026 to Regain Compliance - TipRanks
Finanzdaten der X T L Biopharmaceuticals Ltd Adr-Aktie (XTLB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):